Engineered Calmodulin for Ryanopathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cardiac arrhythmias associated with ryanodine receptor 2 (RyR2) dysfunction, such as catecholaminergic polymorphic ventricular tachycardia (CPVT), face challenges due to lack of cardiac specificity, pro-arrhythmic adverse effects, and insufficient understanding of RyR2 regulation and calcium handling, limiting their broad application and effectiveness.
Innovation Solution
Development of therapeutic calmodulin (TCaM) proteins with altered binding affinity for RyR2, specifically designed to prolong the RyR2 refractory period, which are administered to correct ryanopathies in heart, brain, and skeletal muscle by modifying amino acid residues or using plant calmodulin with higher affinity for RyR2, and delivered via viral vectors for targeted gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacological inhibition of RyR2 is used to treat arrhythmias, then arrhythmia burden is reduced, but cardiac specificity is lacking and pro-arrhythmic adverse effects occur
Solution Approach 1:
The patent applies local quality by engineering calmodulin with tissue-specific binding characteristics. The modified calmodulin is designed to bind preferentially to cardiac RyR2 channels over skeletal muscle RyR1 channels, achieving local specificity at the molecular level. This allows the therapeutic agent to act selectively on cardiac tissue while minimizing effects on skeletal muscle, thereby reducing pro-arrhythmic adverse effects while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent employs parameter changes by modifying the binding affinity parameters of calmodulin for RyR2. Through amino acid substitutions, the calmodulin variant achieves optimized binding strength (Kd values) that enhances RyR2 stabilization without causing excessive inhibition. This parameter optimization allows the therapeutic to effectively reduce arrhythmia burden while avoiding the pro-arrhythmic effects associated with non-selective RyR2 inhibition.
2Reliability
If existing RyR2 inhibitors are used, then Ca handling is improved, but lack of cardiac specificity limits broad application
Solution Approach 1:
The modified calmodulin exhibits local quality through differential binding affinity to isoforms. The molecular structure is engineered to recognize specific features of cardiac RyR2 channels, creating a therapeutic agent that selectively improves cardiac Ca handling while having minimal impact on skeletal muscle RyR1 channels. This isoform-specific action enables broad application in cardiac conditions without compromising skeletal muscle function.
3Reliability
If RyR2 stabilization is achieved through pharmacological agents, then arrhythmia is reduced, but insufficient understanding of RyR2 regulation impedes therapy development
Solution Approach 1:
The patent uses calmodulin as an intermediary molecule to achieve RyR2 stabilization. Rather than directly targeting RyR2 with complex small molecules, the therapy employs calmodulin—a naturally occurring calcium-binding protein—as a mediator that binds to and stabilizes RyR2. This intermediary approach leverages the body's existing regulatory mechanisms, simplifying therapy development while effectively reducing arrhythmia through enhanced RyR2 stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
TCaM proteins effectively prolong the RyR2 refractory period, reducing arrhythmia frequency and severity in CPVT and other ryanopathic conditions, demonstrating therapeutic potential for treating a range of calcium-dependent cardiac and muscular disorders.
Implementation Method 1
TCaM proteins effectively prolong the RyR2 refractory period, reducing arrhythmia frequency and severity in CPVT and other ryanopathic conditions
Data Source
AI summary
Compositions and methods are disclosed for altering the binding affinity of calmodulin for ryanodine receptor 2 (RyR2). As disclosed herein, these therapeutic calmodulin (TCaM) proteins can be used to correct ryanopathies by prolonging the RyR2 refractory period. Therefore, also disclosed is a method for treating a ryanopathy-associated disease in a subject that involves administering to the subject a composition comprising a TCaM disclosed herein.